Most gastrointestinal stromal tumors (GISTs) harbor oncogenic mutations in KIT or platelet-derived growth factor receptor-a. However, a small subset of GISTs lacks such mutations and is termed 'wild-type GISTs'. Germline mutation in any of the subunits of succinate dehydrogenase (SDH) predisposes individuals to hereditary paragangliomas and pheochromocytomas. However, germline mutations of the genes encoding SDH subunits A, B, C or D (SDHA, SDHB, SDHC or SDHD; collectively SDHx) are also identified in GISTs. SDHA and SDHB immunohistochemistry are reliable techniques to identify pheochromocytomas and paragangliomas with mutations in SDHA, SDHB, SDHC and SDHD. In this study, we investigated if SDHA immunohistochemistry could also identify SDHA-mutated GISTs. Twenty-four adult wild-type GISTs and nine pediatric/adolescent wild-type GISTs were analyzed with SDHB, and where this was negative, then with SDHA immunohistochemistry. If SDHA immunohistochemistry was negative, sequencing analysis of the entire SDHA coding sequence was performed. All nine pediatric/adolescent GISTs and seven adult wild-type GISTs were negative for SDHB immunohistochemistry. One pediatric GIST and three SDHB-immunonegative adult wild-type GISTs were negative for SDHA immunohistochemistry. In all four SDHA-negative GISTs, a germline SDHA c.91C4T transition was found leading to a nonsense p.Arg31X mutation. Our results demonstrate that SDHA immunohistochemistry on GISTs can identify the presence of an SDHA germline mutation. Identifying GISTs with deficient SDH activity warrants additional genetic testing, evaluation and follow-up for inherited disorders and paragangliomas.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive tract, but accounts for o1% of all gastrointestinal neoplasms. [1] [2] [3] [4] GISTs are derived from the interstitial cells of Cajal and up to 95% of these tumors express CD117 (KIT). 1, [4] [5] [6] Approximately one-third to half of KIT-negative GISTs stain for DOG-1. 3, 7, 8 The majority of GISTs arise in the stomach (50-60%) and in the small intestine (30%), other tumor sites include the esophagus, large bowel and rectum (10%). 1, 2, 4 Most GISTs (75-80%) harbor oncogenic mutations in KIT (receptor for stem cell factor) and an additional 7% in platelet-derived growth factor receptor-a (PDGFRA). 2, 5, 6, [9] [10] [11] These GISTs respond to targeted imatinib mesylate therapy, which inhibits tyrosine kinase activity. 12, 13 A small subset (10%) of GISTs lacking KIT or PDGFRA mutations are defined as wild-type GISTs. 9 In pediatric patients, 85% of GISTs are KIT/PDGFRA wild-type. These occur mainly in girls, and usually have a clinically indolent course. 4, 9, 14, 15 Unfortunately, wild-type GISTs respond poorly to imatinib. 16 The pathogenetic mechanism in wild-type GISTs is still not clearly understood.
Succinate dehydrogenase (SDH), an enzyme that is involved in the fundamental processes of energy production, participates in both the citric acid cycle and the electron transport chain. 17 SDH functions not only in mitochondrial energy generation, but the genes encoding this enzyme also act as tumor suppressors. SDH consists of the subunits SDHA, SDHB, SDHC and SDHD. Germline mutation in any subunit predisposes individuals to hereditary paragangliomas and pheochromocytomas. 18 In addition, mutations in these genes can also cause GISTs. 9, 10, 19 The familial dyad of paraganglioma and GIST is also known as Carney-Stratakis syndrome. 10, 15 Carney triad describes the association of paragangliomas with GISTs and pulmonary chondromas. 15 GISTs arising in the setting of Carney triad or CarneyStratakis syndrome are also 'wild-type GISTs'. 15 In previous reports, we showed that negative SDHA and SDHB immunohistochemistry reliably identifies pheochromocytomas and paragangliomas caused by germline mutations in SDHA, SDHB, SDHC and SDHD. 20, 21 In addition, Carney-Stratakis and Carney triad associated and wild-type pediatric GISTs can be recognized by SDHB immunohistochemistry. 17, 22 In this work, we performed SDHA immunohistochemistry on 33 wild-type GISTs, including nine pediatric/adolescent GISTs, in order to investigate whether immunohistochemistry could identify SDHA-mutated GISTs.
Materials and methods
Twenty-four adult wild-type GISTs diagnosed in, or referred to, the Erasmus University Medical Center (Rotterdam, The Netherlands) between 1999 and 2011 were included in this study. In addition, seven pediatric and two adolescent wild-type cases from the files of Professor M O'Sullivan, Dublin, were included in this study. We considered a GIST as 'pediatric' if the tumor was diagnosed below the age of 18 years and 'adolescent' if the age at diagnosis was 19-25 years. All these GISTs previously resulted negative for KIT and PDGFRA mutations (KIT: exon 8, 9, 11, 13 and 17; PDGFRA: exon 12, 14 and 18). Clinicopathological features of all these cases are shown in Table 1 . The tissues were used in accordance with the code of conduct Proper Secondary Use of Human Tissue established by the Dutch Federation of Medical Scientific Societies (http://www.federa.org). The Medical Ethical Committee of the Erasmus MC approved the study (MEC-2011-519) .
First, all GISTs were analyzed with SDHB immunohistochemistry. If the tumors were SDHB negative, SDHA immunohistochemistry was performed. Immunohistochemical analysis was performed on 4-5 mm sections of formalin-fixed paraffin-embedded tumor as previously described. 20, 21 Slides were considered suitable if the internal control (granular staining in endothelial cells) was positive.
If a tumor was scored negative with SDHB immunohistochemistry, but stained positive with SDHA, the entire SDHB, SDHC and SDHD coding sequences, including intron-exon boundaries, were analyzed for mutations. If SDHA immunohistochemistry was negative, sequencing analysis of SDHA (NM_004168) was performed. The entire SDHA coding sequence, including intron-exon boundaries, was analyzed for mutations, taking into account the SDHA pseudogenes (NCBI: NR_003263, NR_003264, NR_003265). DNA was isolated according to manufacturer's instructions (Gentra Systems, Minneapolis, MN or AllPrep DNA/ RNA Mini Kit, Qiagen).
When a mutation was found in tumor DNA, the presence of the mutation was also investigated in corresponding germline DNA isolated from paraffinembedded healthy tissue surrounding the tumor. Sequence analysis is a semiquantitative procedure and supplies some information on the relative amount of the mutated-versus the non-mutated-SDHA allele. To substantiate the relative presence of the mutated-and non-mutated-SDHA allele, loss of heterozygosity (LOH) analysis was performed in SDHA-mutated tumors for a polymorphic microsatellite marker at the SDHA locus. For this, PCRs were carried out with fluorescence-labeled primers (Invitrogen, Paisley, UK) (primer sequences are available on request) for 35 cycles with an annealing temperature of 60 1C, and amplified products were analyzed, along with LIZ 500 size standard (Applied Biosystems, Foster City, CA, USA), using capillary electrophoresis on an ABI 3130-XL genetic analyzer (Applied Biosystems). Data were analyzed using GeneMarker software (Soft-Genetics LLC, State College, PA, USA).
Results

Case series
Case 1. A 41-year-old woman was diagnosed with a gastric GIST. Microscopy showed an epithelioid morphology and the tumor cells stained positive for CD117 and DOG-1 during routine diagnostic workup. Sequencing analysis of exons 8, 9, 11, 13 and 17 of the KIT proto-oncogene and exons 12, 14 and 18 of the PDGFRA gene did not reveal mutations. In previous research, this GIST was tested by SDHB immunohistochemistry. 17 The GIST was immunonegative for SDHB and SDHA ( Figure 1 ). Mutational analysis revealed a germline SDHA mutation c.91 C4T leading to p.Arg31X. This patient was homozygous (not informative) for the microsatellite marker, so we could not show LOH, though relative loss of the wild-type allele was seen in the sequencing graph ( Figure 2 , left panel).
At the age of 45, this patient developed a medullary thyroid carcinoma with local lymph nodes and liver metastases. The medullary thyroid carcinoma was positive for SDHB immunohistochemistry, indicating that the tumor was not caused by mitochondrial complex II disruption. Sequencing analysis of the RET gene revealed a mutation p.Met918Thr in the medullary thyroid carcinoma and its metastases, but not in the GIST and the healthy germline tissue of the patient. Somatic mutations are known to occur in up to 40% of sporadic medullary thyroid carcinomas. 23 Cases 2 and 3. Two sisters (respectively, 47-and 53-year-old) were both diagnosed with a GIST located in the stomach. Microscopy of the GIST of sister 1 mainly showed a mixed epithelioid and spindle cell morphology. Tumor cells stained positive for DOG-1 and CD34 and were partly positive for CD117 on routine diagnostic work-up. The tumor of sister 2 showed a spindle cell CD117-and CD34-positive GIST. In both GISTs, no mutations were found in exons 8, 9, 11, 13 and 17 of the KIT gene and exons 12, 14 and 18 of the PDGFRA gene. Tumor cells of both tumors were immunonegative for SDHB and SDHA. Immunohistochemical stainings for CD117 and SDHA of both tumors are shown in the two bottom panels of Figure 3 . Mutational analysis of tumor and germline DNA revealed in both sisters the same SDHA mutation c.91 C4T leading to p.Arg31X. However, relative loss of the wild-type SDHA allele was only seen in sister 1 and not in sister 2 in the sequence (Figure 3 , middle panel). This was confirmed by the LOH analysis, which showed LOH only in the tumor of sister 1 (two upper panels of Figure 3 ). Case 4. A 14-year-old boy was diagnosed with a gastric GIST. Histology showed spindle and epitheloid morphology and CD117 was positive in routine diagnostics. Staining for SDHB and SDHA was negative (not shown). The tumor was defined as wild-type, as no mutations were found in exons 8, 9, 11, 13 and 17 of KIT and exons 12, 14 and 18 of PDGFRA. Mutational analysis revealed a germline SDHA mutation c.91 C4T (p.Arg31X) with no relative loss of the wild-type allele. Indeed, LOH analysis showed no LOH in the tumor (Figure 3 ).
General findings. All nine pediatric/adolescent GISTs were negative for SDHB by immunohistochemistry. Of the 24 adult wild-type GISTs, 7 resulted immunonegative for SDHB (29%). SDHA immunohistochemistry was performed on all SDHBimmunonegative GISTs. One out of nine pediatric/ adolescent GISTs (11%) and three out of twenty-four adult wild-type GISTs (13%) were negative for SDHA immunohistochemistry. Four adult GISTs and eight pediatric/adolescent GISTs were negative for SDHB, but positive for SDHA, by immunohistochemistry. Sequence analysis of these GISTs revealed a germline SDHD missense mutation c.416T4C in one adult tumor leading to a p. Leu139Pro. Figure 2 (right panel) shows the sequencing chromatograms of this SDHD mutation. Sequencing analysis of the remaining 11 GISTs revealed neither mutations nor LOH in SDHB, SDHC or SDHD.
Sequencing analysis of SDHA performed on the four GISTs negative for SDHA immunohistochemistry showed the same SDHA nonsense c.91C4T mutation (p.Arg31X) in all four. Powerplex16 analysis showed that our four SDHA-mutated patients did not share the same alleles (except from the two sisters who showed an overlap of some alleles), excluding contamination (data not shown).
Discussion
The precise role of SDHA as a tumor-suppressor gene in oncogenesis is poorly understood. 24 Oncogenic SDHA mutations have been described in paragangliomas and recently in GISTs. 9, 21, 24 Burnichon et al 24 detected LOH at the SDHA locus in 4.5% of a large series of paragangliomas and pheochromocytomas. Loss of the wild-type allele of SDHA in a tumor from a patient with a germline-inactivating mutation in SDHA indicates that complete loss of SDHA function accompanies tumor formation. In the present study, we found the same SDHA (p.Arg31X) mutation in 1 of 9 (11%) pediatric/adolescent wildtype GISTs and in 3 of 24 (13%) adult wild-type GISTs. This inactivating SDHA mutation can be detected by SDHA immunohistochemistry, as the tumor cells show absent SDHA staining in the presence of positive staining of internal control normal (endothelial) cells. All four identified SDHA mutations were demonstrated to be present in the germline.
Owing to the fact that we found the same SDHA germline mutation in four cases, the possibility of a founder mutation was considered. Three of our investigated patients were from the Netherlands and the fourth was from the United Kingdom. In addition, in an Italian patient the same p.Arg31X was described recently 9 Also, Nannini et al, and Wagner et al, identified the SDHA p.Arg31X mutation (among others) in wild-type and SDHdeficient GISTs, respectively. 25, 26 The frequency of SDHA mutations within the SDH-deficient GISTs (36%) of Wagner et al, is slightly higher, but in accordance with our frequency of SDHA-mutated GISTs that show a negative staining of SDHB (25%).
The occurrence of the SDHA p.Arg31X mutation in three different countries (Italy, United Kingdom and The Netherlands) renders a founder mutation less likely and might suggest a hotspot mutation. The relatively high percentage (12%) of SDHA mutations found in the 33 wild-type GISTs in the present study may be owing to the small sample size and owing to patient selection bias, as Erasmus MC is a tertiary referral center.
Interestingly, the SDHA p.Arg31X mutation has also been identified in a Dutch healthy control group (0.3%). 21 However, as the mutation causes a truncated protein and three of the four SDHAmutated tumors showed loss of the wild-type allele, according to Knudson's two-hit hypothesis, the p.Arg31X mutation seems to be involved in the pathogenesis of the GISTs. It is possible that the mutation is present in healthy controls because of low penetrance of tumor development in SDHAmutation carriers. In our two SDHA-mutated patients without LOH, there is probably a different mechanism responsible for tumor formation, such as inactivation of the wild-type SDHA allele by a somatic mutation or promoter methylation of the wild-type SDHA gene.
Based on previous findings and our present ones of SDHA mutations in wild-type GISTs, we recommend testing for germline mutations of SDHA in all patients diagnosed with wild-type GISTs that are negative for SDHA by immunohistochemistry. 9 The link between paragangliomas, pheochromocytomas and GISTs has been established in the CarneyStratakis syndrome and Carney triad. 10, 15 In CarneyStratakis syndrome, SDHB, SDHC and SDHD mutations have been described. 10 In Carney triad, no mutations in SDH have been found. 27 It has been shown that GISTs from patients with CarneyStratakis syndrome or Carney triad and pediatric GISTs are SDHB negative by SDHB immunohistochemistry. 17, 22, 28 Janeway et al 28 found germline mutations in SDHB, SDHC and SDHD in 6 of 38 wild-type GISTs, but they also found loss of SDHB protein expression in wild-type GISTs without identifiable mutations in SDHB, SDHC or SDHD. This could mean that loss of function of the SDH complex, even without an SDH mutation or deletion, contributes to the pathogenesis of wildtype GISTs. However, the absent SDHB expression in their series might be also owing to SDHA mutations, for which they did not perform mutational analysis. SDH germline mutations were neither found in 66 SDHB-immunonegative wildtype GISTs investigated by Miettinen et al. 19 However, the mutational analysis was not performed on all SDH-deficient GISTs in their series, not all the exons of SDHB, SDHC and SDHD were analyzed and again no mutational analysis of SDHA was performed.
In accordance with Janeway et al 28 and Miettinen et al 19 , we did not find a mutation in SDHB, SDHC or SDHD in three adult GISTs, which were immunonegative for SDHB, but positive for SDHA, in the present study, but we did find an SDHD mutation in one of the cases. Moreover, we did not find any SDHx mutations in eight of nine pediatric/ adolescent GISTs, even though they were all negative for SDHB immunohistochemistry. Possible explanations for the absence of associated SDHx mutations or deletions are mutations in other genes affecting the SDH complex or epigenetic modifications leading to decreased mRNA expression of one of the subunits of the complex. However, we did not compare mRNA expression of SDHB, SDHC and SDHD between the SDHB-immunonegative andpositive cases in our study. In addition, we did not investigate large intragenic deletions of SDHB, SDHC and SDHD in our samples, which can be detected by multiplex ligation-dependent probe amplification analysis. Therefore, large genetic aberrations in the SDHx genes cannot be categorically excluded.
As mentioned before, wild-type GISTs respond poorly to the tyrosine kinase inhibitor imatinib. The finding that loss of function of the SDH complex has a role in a subset of wild-type GISTs could be a new focus for treatment. Moreover, identifying GISTs with deficient SDH activity in patients warrants additional genetic testing, evaluation and follow-up for Carney triad, Carney-Stratakis syndrome and paragangliomas. 19 Imatinib targets the constitutively active tyrosine kinase in GISTs with oncogenic mutations in KIT or PDGFRA. 12 However, the mechanism by which inactivation of one of the subunits of SDH leads to tumorigenesis is still unexplained. Studies suggest that activation of the hypoxic/angiogenic pathway has a role. 29, 30 Possibly, pharmacological agents that target the hypoxia pathway or its downstream targets (such as VEGF, GLUT1 and IGF2) could be used as new treatment options.
In conclusion, germline SDHA mutations are causal for pediatric/adolescent and adult wild-type GISTs in a subset of patients in our series. SDHA immunohistochemistry can be used to detect GISTs with an SDHA mutation and we recommend testing for germline SDHA mutations in all patients with SDHA-immunonegative GISTs. Recognition of SDHmutated GISTs by SDHB and SDHA immunohistochemistry is important for prognosis, treatment and follow-up.
